The aim of this study was to evaluate the
prognostic value of renal function in relation
to amino-terminal portion of the pro-hormone
B-type natriuretic peptide (NTproBNP)
and parameters of cardiopulmonary
exercise testing in predicting mortality and
morbidity in patients with moderate chronic
heart failure (CHF). Sixty-one CHF patients
were included in the study. Patients’ characteristics
were: age 64.3±11.6 years; New York
Heart Association class I/II/III: 14/37/10; left
ventricular ejection fraction: 0.30±0.13 (%);
NT-proBNP: 252.2±348.0 (ng/L); estimated
creatinine clearance (e-CC): 73.6±31.4
(mL/min); estimated glomerular filtration
rate (e-GFR): 66.1±24.6 (mL/min/1.73 m2);
the highest O2 uptake during exercise (VO2–
peak): 1.24±0.12 mL/kg/min; VO2/workload:
8.52±1.81 (mL/min/W)]. During follow up
(59.5±4.0 months) there were 15 cardiac
deaths and 16 patients were hospitalized due
to progression of heart failure. NT-proBNP
and VO2/workload were independently associated
with cardiac death (P=0.007 and
P=0.006, respectively). Hospitalization for
progressive CHF was only associated with
NT-proBNP (P=0.002). The combined cardiac
events (cardiac death and hospitalization)
were associated with NT-proBNP and VO2/
workload (P=0.007 and P=0.005, respectively).
The addition of estimates of renal function
(neither serum creatinine nor e-GFR)
did not improve the prognostic value for any
of the models.In conclusion, in patients with
moderate CHF, increased NT-proBNP and
reduced VO2/ workload identify those with
increased mortality and morbidity, irrespective
of estimates of renal function.
VO2, workload, NT-proBNP, prognosis, chronic heart failure, renal function
Hein J. Verberne, Department of Nuclear Medicine, Room F2-238, Academic Medical Center, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands. Tel. +31.20.5669111 – Fax: +31.20.5669092. E-mail: h.j.verberne@amc.uva.nl
2011-10-25T00:00:00

Trending Topic
Cardiovascular medicine continues to advance at a remarkable pace, driven by innovation, interdisciplinary collaboration and an ever-deepening understanding of disease mechanisms. As patient populations age and chronic conditions become increasingly complex, the field stands at the intersection of precision therapy, digital health and preventive strategy. This winter issue of Heart International reflects that transformation, highlighting […]
Cardiovascular medicine continues to advance at a remarkable pace, driven by innovation, interdisciplinary collaboration and an ever-deepening understanding of disease mechanisms. As patient populations age and chronic conditions become increasingly complex, the field stands at the intersection of precision therapy, ...
Heart failure (HF) is a complex and progressive clinical syndrome that significantly impacts morbidity, mortality and quality of life (QoL).1 On a global scale, HF has become an escalating public health concern, affecting more than 64 million individuals in 2017, and this ...
Heart failure (HF) is a global health burden, with a 2019 prevalence of 711.90 per 100,000 population, totalling 56.19 million cases and 5.05 million years lived with disability, despite only modest declines since 1990.1Â Recent years have shown an uptick in prevalence, driven by ageing populations ...
Functional status refers to an individual’s ability to carry out different levels of activities to meet the needs of daily living.1 Patients with heart failure (HF) commonly have poor functional status that is affected by a number of physical, ...
Heart failure (HF), a prevalent disease, is the common final pathway of several conditions, which result in the activation of numerous neurohumoral pathways. Cardiorenal interaction plays an essential role in the progression of the disease, and the use of diuretics ...
Palliative care (PC) is recommended as a standard of practice for all patients with heart failure (HF) and is supported by evidence of improved patient outcomes (e.g. reduction in symptoms refractory to cardiovascular therapies and improved shared decision-making).1Â PC ...
Heart failure (HF) is a common clinical diagnosis often requiring hospitalization secondary to patient decompensation associated with clinically determined 'dry' or 'wet' volume states. However, fluid overload is the more common basis for clinical deterioration accounting for the majority of ...
Heart failure (HF) is a complex syndrome caused by a variety of cardiac and non-cardiac diseases, and is associated with high mortality and hospitalization rates.1Â Treatment has been traditionally based on a detailed history and physical examination. However, since cardiac ...
Conventionally, according to the European Society of Cardiology pacing and cardiac resynchronization therapy (CRT) guidelines, patients with clinical heart failure and an echocardiographically measured left ventricular (LV) ejection fraction of <35% are considered for CRT implantation or standard right ventricular (...
Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity of HF symptoms, from about 5% of patients in the New York Heart Association (NYHA) ...
Heart failure (HF) is an increasingly prevalent clinical syndrome resulting from a variety of disease processes impeding the heart’s ability to effectively circulate blood. With advances in care and a steadily growing and aging population, HF management is becoming ...
Heart failure (HF) is a highly prevalent and morbid disease in the USA, imposing a significant burden on patients, hospitals and the health system. The prevalence of HF continues to increase, with over 650,000 new HF cases diagnosed annually.1Â There are ...
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.